Tags : inebilizumab-cdon


Viela Bio’s Uplizna (inebilizumab-cdon) Receives the US FDA’s Approval to

Shots: The approval is based on N-MOmentum trial which involves assessing of Uplizna (300mg) vs placebo in 213 patients in the ratio (3:1) at day 1 to day 15 who are anti-AQP4 antibody-positive/negative    The study resulted in anti-AQP4 antibody-positive group remained relapse-free (89% vs 58%) including reductions in NMOSD-related hospitalizations with safety and tolerability […]Read More